Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.

  • 0 views
  • 22 Oct, 2022
  • 1 location
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease. (GENPAD)

Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is

atherosclerosis
clopidogrel
gangrene
intermittent claudication
  • 0 views
  • 29 Apr, 2022
  • 5 locations
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (TAILORED-CHIP)

] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy in patients undergoing high-risk complex PCI as compared with standard Dual Antiplatelet Therapy(aspirin and

aspirin
percutaneous coronary intervention
diabetes
  • 7 views
  • 28 Feb, 2022
  • 14 locations
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI (EPIDAURUS)

challenging. Until recently, triple antithrombotic therapy (TAT) consisting in Aspirin plus Clopidogrel plus OAC was considered the treatment of choice. While efficiently preventing ischaemic events, TAT is

aspirin
ticagrelor
clopidogrel
fibrillation
vitamin k antagonist
  • 0 views
  • 01 May, 2022
  • 2 locations
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) (CAPTIVA)

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke

  • 0 views
  • 21 Oct, 2022
  • 32 locations
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy

chronic renal failure
aspirin
dialysis
  • 0 views
  • 08 Aug, 2021
  • 1 location
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3 (SMART-CHOICE3)

This study is prospective, open-label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of clopidogrel monotherapy as compared with aspirin monotherapy beyond 12 months

aspirin
percutaneous coronary intervention
in stent restenosis
infarct
clopidogrel
  • 0 views
  • 14 Mar, 2022
  • 1 location
Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions

expert consensus, the investigators chose aspirin + Ticagrelor/Clopidogrel for 3-month followed by Ticagrelor/Clopidogrel monotherapy for 3-month to be the antiplatelet regimen in DCB arm. In contrast to

aspirin
ticagrelor
percutaneous coronary intervention
clopidogrel
infarct
  • 0 views
  • 30 Jun, 2021
  • 1 location
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study - ARMYDA-AMULET (ARMYDA-AMULET)

The study will perform a randomized, head-to-head comparison between SAPT (aspirin) and DAPT (aspirin plus clopidogrel) after percutaneous LAA closure with implantation of the Amulet device

  • 0 views
  • 21 Oct, 2022
  • 6 locations
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

randomly receive triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month or 6 months in a 1:1 ratio then quit aspirin till 12 months

aspirin
ticagrelor
percutaneous coronary intervention
clopidogrel
infarct
  • 51 views
  • 03 May, 2022
  • 1 location